ALDH5A1 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt expression of the ALDH5A1 gene in the HAP1 cell line. This product provides a robust loss-of-function model for investigating succinate-semialdehyde dehydrogenase (SSADH) function without relying on single-cell cloning, thereby capturing a diverse spectrum of editing events within a genetically uniform near-haploid background.
The HAP1 cell line is a near-haploid human cell line derived from the male chronic myeloid leukemia (CML) blast crisis cell line KBM-7. Its haploid karyotype facilitates the study of recessive phenotypes, as a single allelic disruption is sufficient to produce a null phenotype. HAP1 cells are widely employed in genetic screening applications and as a model for leukemia research, offering a simplified genomic landscape for precise functional genomics studies.
ALDH5A1 encodes succinate-semialdehyde dehydrogenase, a mitochondrial homotetrameric enzyme that catalyzes the NAD+-dependent oxidation of succinate semialdehyde to succinate, a critical step in the GABA shunt. This reaction is essential for the clearance of the inhibitory neurotransmitter GABA; succinate semialdehyde is generated by GABA transaminase (ABAT) from GABA, and its conversion to succinate by ALDH5A1 feeds the TCA cycle. Loss of ALDH5A1 function leads to accumulation of succinate semialdehyde, which is reduced to gamma-hydroxybutyric acid (GHB), a neuroactive compound that activates GABAB receptors. Thus, ALDH5A1 sits at a key metabolic node linking neurotransmitter catabolism, energy metabolism, and neuromodulation through GHB-mediated signaling.
In the HAP1 background, disruption of ALDH5A1 provides a genetically tractable system to dissect the consequences of SSADH deficiency. The near-haploid nature of HAP1 ensures that knockout phenotypes manifest directly, avoiding confounding effects from a second functional allele. This model enables investigations into metabolic rewiring, mitochondrial dysfunction, and neurotransmitter imbalance in the context of succinic semialdehyde dehydrogenase deficiency (SSADHD). Moreover, the leukemic origin of HAP1 cells allows exploration of potential crosstalk between oncometabolism and GABAergic signaling pathways.
Researchers can employ this ALDH5A1 knockout model in a wide range of functional assays, including western blotting and RT-qPCR for confirmation of gene disruption, enzyme activity measurements to assess residual SSADH function, and quantification of GHB and GABA levels by analytical methods. Metabolic flux analyses and mitochondrial respiration assays can further reveal the impact on TCA cycle activity. The cells also serve as a platform for drug screening studies targeting GHB accumulation or GABAB receptor modulation. Typical applications include modeling SSADHD, investigating neurotransmitter degradation, and exploring metabolic dependencies in cancer. For further technical details or bulk ordering, please contact Ascent Research.
